Lung Cancer | Specialty

Experts Take Stock of Frontline Immunotherapy Combos in NSCLC

January 9th 2020

During an OncLive Peer Exchange program, an international panel of lung cancer experts provided perspective on key findings regarding various immune checkpoint inhibitor (ICI) combinations and data concerning potential biomarkers of response to ICIs in non–small cell lung cancer.

Dr. Saxena on the Importance of Biomarker Testing in ALK+ NSCLC

January 8th 2020

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

Pembrolizumab Combo Hits PFS, But Not OS Endpoint in Frontline Small Cell Lung Cancer

January 7th 2020

The combination of pembrolizumab and chemotherapy improved progression-free survival compared with chemotherapy alone as a first-line treatment for patients with extensive-stage small cell lung cancer.

Expert Reflects on Recent Advances in Lung Cancer

January 3rd 2020

Kaushal Parikh, MD, MBBS, reflects on pivotal lung cancer data shared at recent major oncology meetings.

Poziotinib Misses Primary Endpoint in EGFR Exon 20-Mutant NSCLC

January 3rd 2020

Poziotinib did not meet its primary endpoint of overall response rate in patients with previously treated EGFR-mutant non–small cell lung cancer who have exon 20 insertion mutations.

Dr. Rotow on Brigatinib Safety Profile in ALK+ NSCLC

January 2nd 2020

Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.

Dr. Stinchcombe on Remaining Challenges in ALK+ NSCLC

January 2nd 2020

Thomas E. Stinchcombe, MD, discusses remaining challenges in ALK-positive non­–small cell lung cancer.

Dr. Rizk on the Role of Surgery in Nonmetastatic Lung Cancer

December 23rd 2019

Nabil P. Rizk, MD, MS, MPH, discusses the role of anatomic surgical resection in nonmetastatic lung cancer.

Dr. Levy on Treatments for Oncogenic-Driven NSCLC

December 21st 2019

Benjamin P. Levy, MD, discusses treatment options for patients with oncogenic-driven non–small cell lung cancer.

Dr. Molena on Lung-Sparing Surgery in Early-Stage Lung Cancer

December 19th 2019

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.

FDA Approval Sought for Lurbinectedin in Small Cell Lung Cancer

December 17th 2019

A new drug application has been submitted to the FDA seeking an accelerated approval for lurbinectedin for use as a second-line treatment for patients with small cell lung cancer.

Dr. Liu on the CheckMate-032 Trial in SCLC

December 17th 2019

Stephen Liu, MD, discusses the CheckMate-032 trial in small cell lung cancer.

The Future of SCLC Management

December 17th 2019

Limited-Stage SCLC Ongoing Trials

December 17th 2019

Limited-Stage SCLC Management

December 17th 2019

DLL3-Targeted and Chemo-Sensitive Therapy

December 17th 2019

Second- & Third-line options after Chemotherapy or I/O

December 17th 2019

The CASPIAN Versus IMpower133 Regimen

December 17th 2019

I/O Combination Regimens & the Importance of Biomarkers

December 17th 2019

Novel Agents for R/R and the Future of Extensive Stage SCLC

December 17th 2019